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IMMUNOBIOLOGY
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Chemokine CC motif receptor-like
2 (CCRL2) is a heptahelic transmembrane
receptor that shows the highest degree of
homology with CCR1, an inflammatory
chemokine receptor. CCRL2 mRNA was
rapidly (30 minutes) and transiently
(2-4 hours) regulated during dendritic cell
(DC) maturation. Protein expression
paralleled RNA regulation. In vivo,
CCRL2 was expressed by activated
DC and macrophages, but not by eosino-
phils and T cells. CCRL2/ mice showed
normal recruitment of circulating DC into
the lung, but a defective trafficking of
antigen-loaded lung DC to mediastinal
lymph nodes. This defect was associated
to a reduction in lymph node cellularity
and reduced priming of T helper cell
2 response. CCRL2/ mice were pro-
tected in a model of ovalbumin-induced
airway inflammation, with reduced leuko-
cyte recruitment in the BAL (eosinophils
and mononuclear cells) and reduced pro-
duction of the T helper cell 2 cytokines,
interleukin-4 and -5, and chemokines
CCL11 and CCL17. The central role of
CCRL2 deficiency in DC was supported
by the fact that adoptive transfer of
CCRL2/ antigen-loaded DC in wild-type
animals recapitulated the phenotype ob-
served in knockout mice. These data show
a nonredundant role of CCRL2 in lung
DC trafficking and propose a role for this
receptor in the control of excessive
airway inflammatory responses. (Blood.
2010;116(16):2942-2949)
Introduction
Dendritic cells (DCs) are professional antigen-presenting cells and
key regulators of T-cell functions.1,2 In the airway epithelium,
DCs form an extensive network, where they continuously
sense environmental antigens. After antigen capture, lung DCs
migrate to mediastinal lymph nodes, where antigens are presented
to T cells. Activation of a T helper cell 2 (Th2)–skewed response
by airway DCs is responsible for allergic immune responses
in the lung.3,4
Chemokine receptors play a crucial role in the migration of
maturing DCs to secondary lymphoid organs,5,6 and several
studies have shown that this process is a crucial event for the
appropriate activation of the immune response.7-10 DC migration to
lymph nodes relies on the functional expression of CCR75,6 as well
as other chemotactic receptors, such as CCR8 and BLT1.9-11
In addition, lung DC migration is also regulated by PD1, one of the
2 PGD2 receptors, and by the transcription factors PPR and
Runx3.12-14 However, as a difference from DCs localized in
other anatomical compartments, the homing of lung DCs to
lymph nodes is independent of the action of MRP1, the
LTC4 transporter that regulates CCR7 functions.11 This
finding indicates that DC trafficking is regulated in a
tissue-specific manner.
Chemokine CC motif receptor-like 2 (CCRL2), also known as
L-CCR (lipopolysaccharide [LPS]–inducible CC chemokine-
related gene and Eo1), is a heptahelic serpentine receptor that
shares the highest homology with the chemokine receptors,
CCR1 and CCR5. CCRL2 is structurally characterized by the
presence of a noncanonical DRYLAIV motif. CCRL2 was origi-
nally identified in the mouse macrophage cell line RAW 264.715
and was recently reported to bind the chemotactic protein chemerin,
though in the absence of any detectable intracellular signaling.16
CCRL2 expression at the mRNA level has been described in
murine macrophages,15 glial cells, astrocytes, and microglia stimu-
lated with LPS17,18 and in mast cells.16 CCRL2 was also reported to
be up-regulated in lung macrophages and epithelial cells after
in vivo sensitization.19 The human gene most closely related
to CCRL2 is HCR with its 2 splicing variants, CRAM-A and
CRAM-B.
Here, we describe that CCRL2 is rapidly induced during mouse
DC maturation with a kinetics that precedes CCR7 induction. To
evaluate the relevance of this receptor in DC biology, we generated
CCRL2-deficient mice and used them in an established model of
allergen-induced airway inflammation, in which DCs are known to
play a crucial role.20 The results reported here highlight a nonredun-
dant role for CCRL2 in the migration of lung DCs to regional
lymph nodes and in the induction of Th2-oriented airway allergic
inflammation. These results propose CCRL2 as a new potential
target for therapeutic strategies aimed at controlling lung
hypersensitivity.
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Methods
Dendritic cells
Bone marrow–derived DCs were generated from CD34 bone marrow cells
and were characterized for antigen expression, pinocytic capacity, and
chemotaxis, as previously described.21 Migration of lung DCs was evalu-
ated in sensitized mice by the intratracheal injection of 80 L of fluorescein
isothiocyanate-ovalbumin (FITC-OVA; 10 mg/mL). CD11cFITC DCs
were counted by fluorescence-activated cell sorting (FACS) in mediastinal
lymph nodes 8, 24, 48, and 72 hours later. For adoptive transfer, bone
marrow-derived DCs were pulsed overnight with 100 g/mL OVA, washed,
and instilled intratracheally. In vitro chemotaxis assays were performed
using micro Boyden chambers, as previously described.21
Generation of the CCRL2-deficient mice
A SalI-HindIII and a HindIII-BamHI fragment (6.5 and 3 kb, respectively)
containing the CCRL2 gene, but lacking its open reading frame, were
obtained and ligated to a PGK-neomycin resistance gene cassette. This
construct was electroporated into R1 embryonic stem cells, and resistant
clones were isolated and analyzed by Southern blots after KpnI digestion,
using an external probe. One targeted clone was injected into C57BL/6
blastocysts, and resulting chimeras were mated with C57BL/6 mice
(Charles River Breeding Laboratories) to obtain an outbred line carrying the
mutated CCRL2 allele that was backcrossed in the C57BL/6 background
for 10 generations. Age- and sex-matched littermates were used in all
studies. Procedures involving animals and their care were conformed to
institutional guidelines in compliance with national and international law
and policies (European Economic Community Council Directive; National
Institutes of Health, Guide for the Care and Use of Laboratory Animals.
Quantification of mRNA levels by Northern blot and
real-time PCR
Total RNA was extracted with TRIzol reagent (Invitrogen). Northern blots
were performed, as previously described.21 The ApaI-HincII fragment of
CCRL2 cDNA was used as a probe. The CCR7 probe was obtained as
previously described.21 For real-time polymerase chain reaction (PCR)
analysis, total RNA samples were treated with DNAse I (Invitrogen) before
reverse transcription (RT). Real-time quantitative PCR reactions were
performed on an ABI PRISM 7700 Sequence Detector System (Applied
Biosystems), using a SYBR Green PCR master mix (Applied Biosystems)
and specific primers (supplemental Figure 5, available on the Blood Web
site; see the Supplemental Materials link at the top of the online article).
Gene expression was normalized to -actin or 18S mRNA.
Generation of mAb to CCRL2
First, 107 X-rayed CCRL2/L1.2 cells in phosphate-buffered saline (PBS)
were injected intraperitoneally (i.p.) every other week for 6 weeks into
CCRL2-deficient mice. Three days after the last challenge, spleen cells
were fused following conventional protocols. Hybridomas recognizing
CCRL2/CHO-K and CCRL2/L1.2 transfectants, but not parental cells, were
cloned and tested for specificity on CCRL2, CCRs, and CXCRs transfec-
tants. One hybridoma (hybr 4, IgG2a) was selected for these studies,
purified, and biotinylated.
FACS analysis
Cells were blocked with CD16/32 2.4G2, incubated with biotinylated
anti-CCRL2 antibody (Ab); (3 g/mL), and then with streptavidin-FITC or
-phycoerythrin (PE); (Becton Dickinson). Directly conjugated Abs to
CD3e (145-2C11), CD4 (A15.1.17), CD8 (53-6.7), CD11b (M1/70),
Gr-1 (RB6-8C5), I-A-I-E (2G9), CD11c (HL3), CD80 (16-10A1),
CD86 (GL1), and CD40 (3/23) from Becton Dickinson, CCR7, CD103
(2E7), Siglec H (440c) from eBioscience, and PDCA-1 (JF05-1C2.4.1)
from Miltenyi Biotec were used for analysis of cell subpopulations.
Staining was analyzed by a FACSCanto flow cytometer (Becton Dickin-
son), using CellQuest Pro 5.2.1 software. Flow cytometric analysis of lung
single-cell suspensions was performed as previously described.22
Allergen-induced airway inflammation
Mice were sensitized with OVA (0.01 mg/mouse intraperitoneally)
in 0.2 mL alum on days 0 and 12, exposed daily to OVA aerosol
(5%; 20 minutes) from days 18 to 23, and killed 24 hours after the last
aerosol. Airways were washed 3 times with 1 mL of PBS via a tracheal
cannula. Differential cell counts were performed by using
Diff-Quik–stained cytospins. Cells from lung tissue were obtained after
0.15 mg/mL collagenase (type D; Roche) and 25 g/mL DNase (type I;
Roche) incubation (37°C for 1 hour) as previously described.23 For
histopathology, lungs were fixed in 10% normal buffered formalin. Then,
4-m paraffin-embedded sections were stained with hematoxylin and
eosin. For immunohistochemistry, sections were obtained from frozen
lungs from 3 mice per experimental group. Immunostaining was performed
using anti-CD11c (BD), anti-Siglec H (rat anti–mouse, kindly provided by
Prof M. Colonna, Washington University, St Louis, MO) and anti-CD103
(eBioscience). Primary antibodies were revealed from using anti–hamster
or –rat (Vector Labs) biotin-conjugated secondary antibodies, followed by
streptavidin–horseradish peroxidase (HRP) (for CD11c and Siglec H) or
streptavidin-PA (for CD103) and DAB (all from Dako) or Ferangi Blue
(Biocare Medical).
Airway responsiveness was evaluated 24 hours after the last OVA
challenge by measurements of lung resistance (RL) and dynamic compli-
ance in anesthetized and tracheostomized mice in response to inhaled
methacholine in a Buxco system (Buxco). Goblet cells were counted on
periodic acid-Schiff (PAS)–stained lung sections, using an arbitrary scoring
system, as previously described.24 Data are expressed as mean  SEM,
n  14-15 mice/group. For in vitro antigen restimulation of lymphocytes,
mediastinal lymph nodes were excised, 5  105 cells in 200 L were
seeded in U-bottomed plastic plates, and OVA was added at varying
concentrations; plates were incubated at 37°C for 72 hours.
Cytokine and IgE amount evaluation
Cytokines and total IgE were measured by standard sandwich enzyme-
linked immunosorbent assay (ELISA), from Pharmingen (interleukin
[IL]-4, IL-5, interferon [INF]-, and IgE) and R&D Systems (IL-2, IL-13,
CCL2, CCL5, CCL11, CCL17, and CCL22). OVA-specific IgE were
detected by using anti–mouse IgE monoclonal antibody (mAb; Becton
Dickinson) as the capture antibody and biotinylated OVA (EZ-Link
Sulfo-NHS-LC-Biotinylation Kit; Pierce) as the detection reagent.
Statistical analysis
Statistic significance was calculated by Student t test, Mann-Whitney
U test, and one-way analysis of variance (ANOVA), as appropriate.
Differences were considered significant at P 	 .05.
Results
Regulation of CCRL2 expression in mouse DCs
In a preliminary screening of orphan/uncharacterized putative
chemotactic receptors (unpublished), CCRL2 was selected for its
unique ability to be up-regulated during DC maturation. CCRL2
mRNA was barely detectable in resting bone marrow–derived
myeloid DCs. LPS, a prototypic maturation factor for DCs, rapidly
induced CCRL2 expression, starting at 30 minutes, reaching a peak
at 2 hours, and decreasing thereafter (Figure 1A). As expected,21
CCR7 transcript levels were also increased by LPS, but with
delayed kinetics, starting after 4 hours and reaching peak levels at
24 hours (Figure 1A). Regulation at the mRNA level was paralleled
by protein expression, with peak levels detected at 12 hours that
returned to nearly basal levels at 40 hours of stimulation. The
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evaluation of CCR7 membrane expression confirmed the delayed
kinetics observed at the mRNA level (Figure 1B). Other inflamma-
tory mediators, such as tumor necrosis factor  (TNF) and
poly(I:C), known to induce DC maturation, also up-regulated
CCRL2 expression (Figure 1C). No constitutive CCRL2 mem-
brane expression was detected in CD11c DCs purified from
lymph nodes, spleen, thymus, bone marrow, and lung (data not
shown). However, CCRL2 was readily induced in spleen CD11c
DCs 6 hours after LPS intravenous administration (Figure 1D), a
time frame compatible with the in vivo redistribution of activated
DCs from the marginal zone to the T-cell areas.25
Evaluation of WT and CCRL2/ mice in a model of
OVA-induced airway hyperresponsiveness
To directly evaluate CCRL2 biologic relevance, we generated
CCRL2-deficient mice (CCRL2
/
) by homologous recombination
techniques, as in Figure 2A and B. After electroporation of R1
embryonic stem cells, neomycin-resistant clones were analyzed by
Southern blotting (Figure 2C). Mice were routinely genotyped by
PCR with a set of 3 primers that detected the wild-type (WT) and
the targeted alleles (Figure 2D). CCRL2 deficiency was assessed
by real-time RT-PCR in bone marrow-derived DCs and tissues,
using specific primers (Figure 2E and data not shown). CCRL2
/

mice developed normally to term and were fertile. No significant
alterations were found after histologic and flow cytometric analysis
of lymphoid organs and blood, when compared with age- and
sex-matched WT control mice (not shown). CCRL2
/
 mice had a
normal lifespan and did not show an overt phenotype under
steady-state conditions.
Lung DCs play a crucial role in the transport of antigens to
mediastinal lymph nodes and in the induction of airway hypersensi-
tivity.11,26 The role of CCRL2 was therefore investigated in a model
of airway hypersensitivity. OVA-immunized CCRL2
/
 mice,
challenged by aerosol for 6 consecutive days, showed a dramatic
reduction in the total number of leukocytes and, in particular, of
eosinophils and lymphocyte/mononuclear cells, with respect to WT
animals (Figure 3A). The decrease in T cells was evident for 3 main
cell subsets, namely CD4, CD8, and ST2CD3/Th2 cells
(Figure 3B). However, a possible direct role for CCRL2 in the
recruitment of eosinophils and T cells into the airways was ruled
out by the lack of expression of CCRL2 in these 2 cell types;
conversely, BAL MHCII cells (macrophages and DCs) expressed
CCRL2 (Figure 3C).
In parallel, the BAL of CCRL2
/
 mice contained lower levels
of the Th2 cytokines IL-4 and IL-5 and similar levels of IL-13 and
the Th1 cytokine IFN (Figure 3D). Of note, although Th2 cells
and eosinophils represent an important source for Th2 cytokines,
IL-13 can also be secreted by lung smooth muscle cells.27 This may
explain the different regulation of IL-13 versus IL-4 and IL-5
observed here. The alterations observed in the BAL were not
paralleled by changes in the lung parenchyma, where normal
degrees of infiltrating leukocytes (supplemental Figure 1A-B) and
cytokine levels were detected (supplemental Figure 1C). To further
examine the mechanisms associated with the defective leukocyte
recruitment observed in CCRL2
/
 mice, the levels of some
relevant chemokines were evaluated. The eosinophil-attracting
Figure 1. Induction of CCRL2 in maturing DCs. DCs were generated in vitro from
CD34 bone marrow precursors. (A) Total RNA was purified from immature DC
(0 hours) or DC treated for different times with 100 ng/mL LPS and analyzed by
Northern blot. Ethidium bromide staining is shown. (B) Kinetics of CCRL2 and CCR7
membrane expression in DC stimulated with 100 ng/mL LPS. The graphs show the
mean fluorescence intensity (MFI) of cells labeled with CCRL2 and CCR7 mAbs.
(C) FACS analysis of DCs treated with 100 ng/mL LPS, 20 ng/mL TNF, or 25 g/mL
poly (I:C) for 12 hours. Data are expressed as folds of increase of CCRL2 labeling
over vehicle-treated DC. (D) CCRL2 expression in spleen CD11c DCs isolated
6 hours after intravenous injection of 25 g/mouse of LPS. Histograms represent
CCRL2 expression in WT (dotted line) and CCRL2
/
 mice (solid lines). Data are
representative of 2-4 separate experiments.
Figure 2. Generation of CCRL2 deficient mice. (A) Exon/intron structure of the
CCRL2 gene. (B) Schematic representation of WT and KO alleles of the CCRL2 gene
and targeting vector. Restriction sites: K, KpnI; S, SalI; H, HindIII; B, BamHI; Sa, SacI;
Sc, ScaI. KpnI-digested genomic DNA fragments were detected by a specific probe.
(C) Southern blot analysis of KpnI-digested genomic DNA from transfected embry-
onic stem cells hybridized with the CCRL2 probe generated a 12-kb WT restriction
fragment and a 3.5-kb homologous recombinant restriction fragment. (D) PCR
analysis of genomic DNA of CCRL2/ (lane 1), CCRL2
/
 (lanes 2 and 3), and
CCRL2/
 (lane 4) mice. (E) Total RNA was isolated from immature as well as
TNF-– and LPS-stimulated (24 hours) bone marrow DCs.
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chemokine, CCL11/eotaxin, and the Th2-attracting chemokine
CCL17/TARC levels were significantly decreased in BAL (Figure
3D), but not in lung tissue (supplemental Figure 1C). This finding
is consistent with the decreased number of eosinophils and
Th2 cells observed in the airway lumen. Conversely, no difference
was observed in the expression of CCL22 (BAL and lung) and
CCL11 and CCL17 in the lung. CCL2 and CCL5 levels were
decreased in lung tissues of OVA-sensitized CCRL2
/
 (supplemen-
tal Figure 1C), but not in the BAL (Figure 3D). In addition,
OVA-sensitized CCRL2
/
 mice showed normal levels of circulat-
ing total and OVA-specific IgE (Figure 3E). This finding is
consistent with the ability of CCRL2
/
 mice to mount a normal
primary and secondary antibody response after intraperitoneal
immunization with OVA/Alum or OVA/complete Freund’s adju-
vant (unpublished results). Finally, the typical features of asthma,
namely, airway hyper-responsiveness (AHR) and mucus hyperse-
cretion, were assessed in OVA-sensitized CCRL2
/
 and WT mice.
Both strains showed a significant increase in methacholine respon-
siveness evaluated as lung resistance (Figure 3E) and dynamic
compliance (data not shown) that was, however, similar in the
2 mouse strains (Figure 3E). Similarly, OVA-sensitized CCRL2
/

and WT mice displayed a comparable number of goblet cells
(Figure 3E).
Defective trafficking of pulmonary CCRL2/ DCs to regional
lymph nodes
The migration of lung DCs from periphery to regional lymph nodes
is a key step for the induction of immune response and toler-
ance.5,6,28 Therefore, lung DC trafficking was investigated in
OVA-challenged CCRL2
/
 mice. In agreement with previous
reports,29 Figure 4A shows that the influx of DC into the lung was
already detectable after 2 hours of OVA challenge and reached peak
levels at 24 hours. No significant difference in the absolute number
of DCs (Figure 4A) in their activation phenotype (ie, CD80, CD86,
CD40, and MHCII expression; data not shown) was found between
CCRL2
/
 and WT mice at any of the time points investigated.
Similarly, no difference was observed in the relative proportion of
the 3 major lung DC subsets, namely, myeloid CD103 and
CD11b DC and plasmacytoid DC (Figure 4B). Furthermore, the
Figure 3. Role of CCRL2 in OVA-induced airway
inflammation. WT and CCRL2
/
 mice were sensitized
and challenged with OVA by aerosol. BAL was collected
24 hours after the last aerosol. (A) Differential cell counts
in BAL. (B) Evaluation of T-cell subsets in BAL.
(C) CCRL2 membrane expression by MHCII cells,
eosinophils, and T lymphocytes by FACS analysis.
Histograms represent CCRL2 mAb staining of cells from
WT (filled curves) and CCRL2
/
 mice (open curves).
(D) Cytokine and chemokine levels in BAL. (E) Total and
OVA-specific IgE in serum (left panel) and bronchial
hyperreactivity (AHR) to methacholine (middle panel)
and mucus production (right panel). Data are
mean  SEM of 5 (A) or 3 (B-E) representative experi-
ments with 6-12 mice per group. * P 	 .05; ** P 	 .01.
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in vivo distribution of DC subsets was investigated by immunohis-
tochemistry of lung frozen tissue sections. CD103 cells were
mainly identified in the peribronchiolar space lining the conducting
airways. Siglec H and CD11c cells were localized in the
peribronchiolar space admixed to other immune cells as well as in
the interstitial space of the lung parenchyma. CD11c stain was also
observed in large cells located in the alveolar space, likely
reflecting expression by alveolar macrophages. However, no differ-
ence was observed between WT and CCRL2
/
 mice in the
distribution of these DC subsets in either resting or OVA-
stimulated conditions (supplemental Figure 2). To study the
migration of airway DCs, OVA-sensitized animals were instilled
intratracheally with a single administration of FITC-OVA, and
CD11cFITC DCs were enumerated in mediastinal draining
lymph nodes.4,23 Figure 4C and D report that the migration of
FITC DCs was already detectable after 8-hour stimulation and
reached a peak at 24 hours, as previously reported.23 CCRL2
/

mice showed a statistically significant reduction in FITC
DC trafficking to lymph nodes at 48 and 72 hours after antigen
administration; of note, only FITC DCs expressed CCRL2
(Figure 4E). These results highlight a crucial role of CCRL2 in
directing pulmonary DC migration to draining lymph nodes. To
investigate the molecular basis for the defective migration of lung
DCs, experiments were performed by using bone marrow–derived
DCs. In vitro, DCs generated from CCRL2
/
 and WT bone
marrow progenitors were similar in terms of cell yield (not shown),
expression of membrane markers, and costimulatory molecules,
and in their ability to take up antigens (supplemental Figure 3A-B).
These results postulate that CCRL2 deficiency does not interfere
with DC development and maturation in vitro. CCRL2
/
 DCs
were also tested for the expression and function of chemotactic
receptors. When evaluated at the mRNA level, CCRL2
/
 DCs
showed a normal expression of the chemokine receptors,
CCR1, CCR2, CCR5, CXCR4, and CXCR6, and CCR7
(supplemental Figure 3C). Expression of CCR-3, -4, -6, -8, -9,
CXCR-2, -3, -5, -6, -7, CX3CR1, and XCR1 was low in both WT
and CCRL2
/
 DCs (less than 500 mRNA molecules per
106 -actin molecules) and was not modulated during maturation
(data not shown). When tested in chemotaxis assays, immature
CCRL2
/
 DCs showed a normal in vitro migration to CCL5 and
chemerin, and a slightly reduced response to CCL3 and CXCL12.
Mature CCRL2
/
 DCs were competent in migrating to CCL19, a
CCR7 ligand (Figure 4F). Finally, skin-painting experiments did
not reveal any alteration in the in vivo migration ability of
endogenous CCRL2
/
 DCs, and no alteration was seen in the
migration to lymph nodes of in vitro generated carboxyfluorescein
succinimidyl ester-labeled DCs (from WT and CCRL2 mice),
when injected in the footpads of WT mice (data not shown).
Altogether, these results exclude the possibility that CCRL2
Figure 4. Role of CCRL2 in lung DC trafficking.
(A) Lung tissue and trachea were isolated from sensi-
tized mice after one OVA-aerosol challenge. DCs were
quantified by FACS analysis. Results are expressed
as total number of DCs per mouse (mean  SEM,
n  3; 6 mice/group). (B) The percentage of CD11c/
low autofluorescent DCs in total lung CD11c cells and
DC subsets (CD103, CD11b, and Siglec H/PDCA1
pDCs) are presented. (C-D) OVA-sensitized mice re-
ceived intratracheally 800 g of OVA-FITC. (C) Repre-
sentative analysis of WT and CCRL2
/
 mediastinal
lymph node cells obtained 48 hours after FITC-OVA
administration. (D) Kinetics of FITC DCs in lymph
nodes. Data are mean  SEM, n  3; 12-15 mice/
group. *P 	 .05. (E) Surface expression of CCRL2 in
lymph node FITC and FITC
 WT DCs after OVA-FITC
administration (n  2; 4 mice/group). (F) Chemotaxis of
bone marrow–derived DCs. One experiment representa-
tive of 6, each one performed with independent DC
cultures. Results are at the net of basal migration
(10  3 and 8  2 cells for WT and KO cells, respec-
tively. *P 	 .05).
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deletion may be associated to a major alteration in the expression
and function of DC chemotactic receptors.
Defective lymphocyte priming in mediastinal lymph
nodes of CCRL2/ mice
The anti-OVA specific immune response was evaluated using cells
collected from lung draining lymph nodes. For this purpose, lymph
nodes were collected 24 hours after the last aerosol challenge and
homogenized, and cell suspensions analyzed. Consistently with the
reduced migration of antigen-loaded DCs,30 mediastinal lymph
nodes from CCRL2
/
 mice showed a 2-fold reduction in total
cellularity and a significant reduction in the percentage of total
CD11c cells (Figure 5A). Lymph node cell suspensions were then
exposed to OVA, and Th1/Th2 cytokine levels were assessed in
culture supernatants. As shown in Figure 5B, at the end of 4-day
culture, WT cells secreted IL-5 and IL-13 at levels that were
significantly higher than those detected using cells from CCRL2
/

lymph nodes. In the same experiments, IL-4 and IFN levels were
below the assay detection limit.
To directly investigate the role of CCRL2 in the elicitation of
the Th2 response in vivo, WT mice were sensitized with OVA at
days 0 and 11, and at days 18 and 20, received the intratracheal
injection of OVA-pulsed DCs generated from either WT or
CCRL2
/
 mice. Forty-eight hours after the last DC instillation,
mediastinal lymph node cells were collected and cultured in vitro in
the presence of OVA. As shown in Figure 5C, cells obtained from
mice that had received WT DCs showed a strong Th2 response in
terms of IL-5 and IL-13 production that was not further stimulated
by the in vitro addition of OVA. The lack of response to OVA in
vitro is possibly due to the high concentration of the antigen used to
load DCs before adoptive transfer. On the contrary, lymph node
cells from mice that had received CCRL2
/
 DCs showed very
modest response that could be elicited in a dose-dependent manner
by the in vitro addition of OVA (Figure 5C). Cells from lymph
nodes of mice instilled with un-pulsed WT or CCRL2
/
 DCs did
not produce IL-5 or IL-13 both under basal conditions and in
response to OVA (not shown). The defective ability of CCRL2
/

DCs to prime a Th2 response could not be ascribed to an intrinsic
defect of CCRL2
/
 DCs, since they were fully able to induce
T-cell proliferation in allostimulatory mixed leukocyte reactions
(MLRs). Indeed, supplemental Figure 4A shows similar levels of
carboxyfluorescein succinimidyl ester-labeled CD4 cell prolifera-
tion when cultured with either allogenic WT or CCRL2
/
 DCs.
Similarly, CCRL2
/
 DCs induced a normal degree of OT-II
OVA-specific TCR transgenic CD4 T-cell proliferation in vitro
(supplemental Figure 4B). In agreement with these results, similar
levels of cytokines (IL-2, IL-4, and IFN-) were detected in the
supernatants of T-cell cultures performed with WT and CCRL2
/

DCs (supplemental Figure 4).
Discussion
The migration of lung DCs from periphery to mediastinal lymph
nodes is a key step in the development of airway allergy and
inflammation, including asthma.3,4,11,31 In this study, we report that
the expression of the poorly characterized receptor, CCRL2, is
rapidly induced during DC maturation, both in vitro and in vivo,
with kinetics that precede CCR7 expression, the master lymph
node homing chemokine receptor.5,6 To investigate the potential
role of CCRL2 in DC biology, we have generated CCRL2-deficient
mice and used them in an established Th2 model of OVA-induced
airway inflammation, in which DC migration was shown to play a
prominent role.3,6 In this experimental model, antigen-loaded DCs
revealed an impaired capacity to traffic to regional lymph nodes
and this defect was associated with reduced T-cell priming. CCL11
and CCL17 were also significantly reduced in the airways of
CCRL2-deficient mice. CCL11 has been shown to be an important
chemoattractant for eosinophils and Th2 cells, whereas CCL17 is a
chemoattractant for Th2 cells.32 Therefore, the decreased produc-
tion of these 2 cytokines likely accounts for the reduced number of
these 2 cell types in the airway lumen of CCRL2
/
 mice. Indeed,
lung eosinophils and T cells do not express CCRL2, ruling out a
direct involvement of this receptor in their recruitment. In the lung,
CCL11 and CCL17 are produced by epithelial and endothelial
cells, whereas smooth muscle cells and alveolar macrophages are
responsible for the production of other chemokines, such as CCL2,
CCL12, and CCL22.31,33 CCRL2 is expressed by bronchial epithe-
lial cells and lung macrophages after OVA challenge.19 Therefore,
it is possible that CCRL2 deficiency in these additional cell types
might also contribute to the reduced airway inflammation observed
in CCRL2
/
 mice. On the contrary, the degree of leukocyte
infiltration and the levels of CCL11 and CCL17 in lung tissue were
not altered.
The levels of the Th2 cytokines, IL-4 and IL-5, were reduced in
both the airway lumen and the lung interstitium, highlighting a
defect of CCRL2
/
 mice in generating Th2 responses. Consis-
tently with these results, T-cell priming in mediastinal lymph nodes
was almost abolished in CCRL2
/
 mice. Since lung antigen-
Figure 5. Impaired production of Th2 cytokines in mediastinal lymph nodes of
CCRL2/ mice. Lymph nodes single-cell suspensions were obtained 24 hours after
the last aerosol administration. (A) Total cells/mouse and percentage of DCs in
gated CD11cMHCII cells. (B) Lymph node cells were cultured (0.5  106 cells/0.2
mL/well) with OVA for 96 hours. (C) WT or CCRL2
/
 OVA-pulsed bone marrow DCs
(106 cells/mouse) were injected intratracheally into WT mice at days 18 and
20. Forty-eight hours later, lymph nodes were excised and cytokine production
determined after ex vivo stimulation with OVA. Data are mean  SEM of
10-20 mice/group from 2 separate experiments. *P 	 .05; **P 	 .01 in comparison
to WT mice. # indicates undetectable levels.
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specific T-cell response is initiated in the lymph nodes, these results
suggest a critical role for CCRL2 in the generation of local primary
immune responses.
Indeed, adoptive transfer experiments of antigen-loaded
CCRL2
/
 DCs into WT animals support the concept that the
defective Th2 priming in mediastinal lymph nodes was strictly
associated to a defect in DC trafficking. On the other hand, the
recruitment of circulating DCs to the lung of CCRL2
/
 mice
exposed to OVA was not different from that of WT animals. This
result suggests that this receptor is not involved in the tissue
recruitment of peripheral DCs. Bone marrow-derived DCs gener-
ated from CCRL2
/
 mice were indistinguishable from WT mice
in terms of antigen uptake, membrane phenotype, and antigen
presentation capacity. Furthermore, CCRL2
/
 DCs expressed
normal mRNA levels of all the chemokine receptors investigated
and normal in vitro and in vivo migration properties, excluding the
possibility that CCRL2 deletion might be associated with a more
general alteration of the chemotactic receptor functions. Finally, it
should be noted that in vitro, DCs obtained from CCRL2
/
 mice
were fully competent in promoting the proliferation of allo- or
syngeneic OT-II cells and in inducing Th2 cytokine production.
Taken together, these results exclude an intrinsic defect of
CCRL2
/
 DCs to promote T-cell activation and support a role for
CCRL2 in lung DC migration and function. Despite the reduced
cell recruitment in BAL and of the reduced Th2 priming in lymph
nodes, lung function, assessed as methacholine responsiveness,
was only slightly decreased. These findings suggest that, in this
model, lung function correlates better with the leukocyte content of
lung parenchyma, rather than the airway lumen. Indeed, previous
studies have shown that blocking CCL12 or CCL22 reduces
leukocyte recruitment to the lung interstitium, but not to the airway
lumen; this defect was associated with a decrease in airway
hyper-responsiveness and mucus production.34,35 Of note,
CCRL2
/
 mice did not show any alteration when tested in a Th1
model of OVA/LPS-induced lung hypersensitivity36 (data not
shown). This result highlights a peculiar role of CCRL2 in
Th2-skewed responses.
In the past few years, it has been proposed that CCL2, CCL5,
CCL7, and CCL8 could bind and activate CCRL2.37 However, we
(data not shown) and others16 have not been able to confirm these
data. Of note, we have previously reported that maturation of
mouse DCs in vitro causes a marked decrease in the chemotactic
response toward CCL2 and CCL5,21 whereas this study reports that
CCRL2 is induced during maturation. CCRL2 presents a noncanoni-
cal DRYLAIV motif and the ability of this receptor to signal is still
a matter of debate. It was recently shown that CCRL2 binds and
presents chemerin in the absence of receptor internalization and
signaling.16 Chemerin is a chemotactic protein that we and others
have recently purified and characterized as the ChemR23
ligand.38,39 This study reports that chemerin induces the in vitro
migration of WT and CCRL2
/
 DCs, and does not modify the
migration to CCR7 ligands (unpublished data). Chemerin expres-
sion in mediastinal lymph nodes was not modulated by OVA
immunization and challenge in WT and CCRL2
/
 mice (data not
shown); therefore, the role of chemerin in the trafficking of
CCRL2 lung DCs is presently uncertain.38
The migration of DCs from peripheral tissues to draining lymph
nodes relies on the functional expression of CCR7 and CCR8.5,6,26
However, CCR7 proper functioning requires accessory signals. In
particular, it was reported that cysteinyl leukotrienes and their
transporter protein, MRP1, were required for CCR7 activity.40 We
have recently reported that also LTB4, through the activation of its
high-affinity receptor, BLT1, promotes CCR7 expression and
function in migrating DCs.9 Recent work has proposed that DC
trafficking from peripheral tissues is controlled in a tissue-specific
manner, with lung DC egression being independent of the expres-
sion of MRP1.11 In this article, we show that lung DC migration is
impaired in CCRL2-deficient mice. However, we did not observe
any defect in the migration of skin DCs in a model of FITC-skin
painting and using CCRL2
/
 bone marrow-derived DCs injected
in the footpads of WT mice (data not shown). Therefore, we
propose that MRP1-independent lung DC trafficking to lymph
nodes may require a still-unknown accessory signal provided by
CCRL2.
In summary, this study reports that CCRL2 plays a nonredun-
dant role in lung DC migration to peripheral lymph nodes, and that
this defective DC migration is responsible for the reduced Th2
response observed in CCRL2
/
 mice. Therefore, CCRL2 may
represent a new target for the control of lung inflammatory
responses.
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